Clinical Trials Logo

Musculoskeletal Cancer clinical trials

View clinical trials related to Musculoskeletal Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT04347122 Completed - Sarcoma,Soft Tissue Clinical Trials

Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

Start date: January 28, 2020
Phase: Phase 4
Study type: Interventional

This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.

NCT ID: NCT01696760 Completed - Soft Tissue Sarcoma Clinical Trials

Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology

Start date: October 2010
Phase: N/A
Study type: Interventional

This is a research study to compare the efficacy of aspirin (acetylsalicylic acid) and pneumatic compression devices versus enoxaparin (also known as Lovenox) and pneumatic compression devices in preventing deep vein thrombosis in patients with pelvic and lower extremity malignant tumors and undergoing surgery. Pneumatic compression devices are also known as sequential compression devices and are inflatable compression sleeves that are placed around patient's legs to reduce the risk of clot formation deep vein thrombosis. Pneumatic compression devices are made of a soft material that wraps around the lower leg and periodically squeeze the calf. A deep vein thrombosis is a blood clot. Most hospitalized patients wear these as a preventive measure. Pneumatic compression devices alone are not sufficient to prevent deep vein thrombosis formation. Therefore, medicines, such as aspirin and enoxaparin are utilized. Both drugs are used for prevention, but there are no studies in patients with musculoskeletal tumors which have determined whether one drug is better than another. The knowledge gained from this study will determine whether aspirin and pneumatic compression devices is the same or better than enoxaparin and pneumatic compression devices in preventing deep vein thrombosis in this patient population and may result in fewer wound and bleeding complications